The transforming growth factor beta (TGF-beta) pathway regulates vascular remodeling and mutations in its receptor genes, TGFBR1 and TGFBR2, cause syndromes with thoracic aortic aneurysm (TAA).
("Surrozen” or the "Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced a strategic ...
Jefferies initiated coverage of Keros Therapeutics (KROS) with a Buy rating and $107 price target The firm says Keros has expertise in the TGF-beta pathway, which plays roles in blood, lung and ...